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Abstract
Background: Maternal circulating levels of anti-angiogenic factors such as soluble fms-like tyrosine kinase-1 (sFlt-1),
endoglin (sEng) and placental proteins like activin A and inhibin A are increased before the onset of pre-eclampsia. There is
evidence for oxidative stress in pre eclampsia. Recently it was shown that placental oxygen concentration is related to sFlt-1
and inhibin A. In addition it is reported that oxidative stress markers are increased in placental tissue delivered after labour.
Therefore, the objective of this study is to investigate if these proteins are altered in maternal circulation of labouring pre-
eclampsia and normal pregnancies.
Methodology: To assess the effects of labour, samples were taken from 10 normal pregnant (NP) and 10 pre-eclamptic (PE)
women pre-labour, full dilation, placental delivery and 24 h. To assess the effects of placental delivery, plasma samples were
taken from 10NP and 10PE women undergoing elective Caesarean section, pre-delivery, placental delivery and 10 min,
60 min and 24 h post delivery. SFlt-1 and sEng and activin A and inhibin A were measured using commercial and in house
ELISA’s respectively.
Results: The levels of sFlt-1 and sEng were significantly higher in PE compared to NP women in both groups. In labour, sFlt-
1 levels increased significantly at full dilatation in PE women, before declining by 24 hr. However there was no significant
rise in sEng levels in labour. Activin A and inhibin A levels declined rapidly with placental delivery in NP and PE pregnancies.
There was a significant rise in activin A levels during labour in PE compared to pre labour, but inhibin levels did not increase.
Conclusion: Labour in pre-eclamptic women increases the levels of sFlt-1 and activin A. This pilot data suggests that increase
in the maternal levels of these factors in labour could predict and/or contribute to the maternal syndrome postpartum.
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Introduction
Pre-eclampsia is a pregnancy specific complication and a major
cause of maternal and fetal morbidity and mortality. Early stages
of placental development occur under relatively hypoxic condi-
tions [1] that favour invasive cytotrophoblast proliferation [2].
Invading cytotrophoblasts are pivotal in the transformation of the
maternal uterine circulation. In normal pregnancies, the transfor-
mation of the spiral arteries is completed around mid gestation in
order to optimise the distribution of maternal blood into low
resistance uterine vascular network and ultimately inside the
placental intervillous chamber [3].
In pre-eclampsia, there is defective early trophoblastic invasion
of the decidua due to failure of conversion of the spiral arteries into
low-resistance channels. This results in retention of vasoreactivity
within the placental vascular bed which causes diminished and
variable perfusion to the intervillous space [4–6]. The magnitude
of defective trophoblastic invasion of the spiral arteries correlates
with the severity of the hypertensive disorder [7]. The mechanism
that leads to the invasion and transformation of the spiral arteries
by trophoblasts in normal pregnancy and the factors that restrict
trophoblast invasion in pregnancy complications such as pre-
eclampsia are poorly understood.
Within the last decade, several studies have investigated possible
biochemical markers altered in pre-eclampsia [8–9]. TGF beta
proteins produced by the placenta and vascular endothelial cells
are involved in cell proliferation and differentiation. High
concentrations of inhibin A and activin A are found in the
maternal circulation and the placenta is thought to be the
predominant source [10–12], although activin A is also produced
by peripheral mononuclear cells and vascular endothelial cells
[13]. In women with established pre eclampsia, circulating levels of
inhibin A and activin A are significantly elevated compared to
normal pregnancy [12] and studies have shown serum levels can
be raised as early as 10–15 weeks of pregnancy in women who
subsequently develop pre-eclampsia [14].
More recently, pro and anti angiogenic proteins have been
investigated in maternal circulation of pre-eclampsia patients [15].
PLoS ONE | www.plosone.org 1 February 2009 | Volume 4 | Issue 2 | e4453Vascular endothelial growth factor (VEGF) is an important
angiogenic protein in pregnancy. Placental growth factor (PlGF) is
a placental protein that potentiates the effect of VEGF [16]. Soluble
fms-like tyrosine kinase 1 (sFlt-1), also known as soluble vascular
endothelial growth factor (VEGF) receptor1 is an anti-angiogenic
protein that is increased prior to the onset of the clinical disease in
women with pre-eclampsia. sFlt-1 levels correlate with the severity
and the time to the onset of the disease [15–18]. Soluble Endoglin
(sEng) is a novel anti-angiogenic protein. It is a cell surface
coreceptor for transforming growth factor -b1 and -b3 isoforms and
is expressed highly in endothelial cells and the trophoblast [19]. Its
levels have been shown to rise in the last two months of normal
pregnancy, however the levels rise earlier and more steeply in
women who go on to develop pre-eclampsia, reaching a peak at the
onset of clinical disease[15–16,20–21].
In pre-eclampsia, there is increased oxidative stress and
maternal systemic inflammation [22–23]. The mechanism behind
the increases in these hormones is unknown, although placental
hypoxia has been shown to alter activin A and sFlt-1 levels in vitro
[24–25]. Recently it has been shown that oxidative stress
stimulates activin A production and secretion from placental
explants and endothelial cells and that in women with pre-
eclampsia, circulating levels of activin A are significantly associated
with markers for excessive oxidative stress [26]. At parturition,
activin A has also been shown to be increased in labour compared
to an elective Caesarean section at term [27].
An aspect of pre-eclampsia which is intriguing is the
development of hypertension postpartum. Hypertension arising
de novo in the postpartum period in women who did not have
hypertension in the antepartum period could be a non-specific
phenomenon in women with no underlying disease. However, it
could also be late onset pre-eclampsia or the unmasking of
underlying essential hypertension. The British Eclampsia Survey
[28] reported an incidence of 18% intrapartum, and 44%
postpartum eclampsia. The majority of postpartum eclamptic fits
occurred within the first 48 hours after delivery. Only 12%
presented after this period and indeed only 2% of cases occurred
after seven days postpartum. Another severe form of pre-eclampsia
is HELLP syndrome and a third of these cases are diagnosed for
the first time postpartum [29]. These cases are also known to
worsen postpartum prior to clinical improvement.
The fact that pre-eclampsia and eclampsia can occur in the
postnatal period raises the question as to the role of placental
factors which could predict and/or contribute to the maternal
syndrome postpartum. The objective of this study was to
investigate the effect of the labour and the removal of the placenta
on the circulating concentrations of inhibin A, activin A, sFLT-1
and sEng. In addition, we studied the relative contributions of
these proteins in pre-eclampsia and normal pregnant women as
the release of these molecules could be a potential trigger to
postpartum worsening of pre-eclampsia.
Materials and Methods
Subjects
To investigate the effect of labour, patients undergoing
induction of labour were recruited (Table-1). They were diagnosed
by new hypertension in pregnancy (blood pressure $140/
90 mmHg, on at least two occasions at least six hours apart) and
new proteinuria ($2+ on dipstick testing on at least two occasions
or $500 mg protein in a 24 hour urine collection, in the proven
absence of a urinary tract infection). Peripheral venous blood
samples were taken [1] before induction of labour, [2] at full
dilatation confirmed by a vaginal examination by the midwife or
by visible signs of onset of second stage, [3] immediately after
placental delivery and [4] 24 hours after delivery. All patients
recruited in this group (10 normal pregnant and 10 pre-eclampsia
women) delivered vaginally.
To investigate the effects of placental separation alone, ten pre-
eclamptic women scheduled for Caesarean section were recruited
from hospital in-patients (Table-2). Ten healthy pregnant women
scheduled for elective Caesarean section for breech presentation or
previous Caesarean section in the third trimester of pregnancy
were recruited as controls. They had no significant past medical
history, current illness or used regular medication. Peripheral
venous blood samples were taken [1] prior to Caesarean section,
[2] at the time of placental delivery, [3] 10 min post delivery, [4]
60 min post delivery and [5] 24 hour post placental delivery.
Table 1. Labour study.
Patient characteristics Normal pregnant Pre-eclamptic women P value
N=10 N=10 Mann Whitney U test
Maternal age (years) 30 (4.9) 32 (4.9) Ns
Nulliparity (%) 50 80 -
Gestation at sampling/delivery (weeks) 41 (1.6) 37 (1.4) ,0.001
BMI 23.9(0.9) 29.04(1.8) ,0.05
Smoking none none -
Diastolic BP at sampling (mmHg) 73(5.2) 93 (16.0) ,0.01
Systolic BP at sampling (mmHg) 120 (8.2) 140 (19.6) ,0.001
Maximum diastolic BP (mmHg) 84 (6.2) 111 (9.1) 0.001
Maximum systolic BP (mmHg) 133 (7.3) 174 (13.0) 0.0001
Maximum 24 hr proteinuria (gms) Not available 881(510–3027) -
Birthweight (g) 3606 (456) 2626 (525) 0.001
Placental weight (g) 682 (115) 612 (144.4) 0.05
SGA (Birth weight ,10
th centile for gestation) none 40% -
doi:10.1371/journal.pone.0004453.t001
TGF Beta Proteins in Labour
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full written information about the research project. This study was
approved by the OxREC (Oxfordshire Clinical Research Ethics
Committee).
Measurement of Activin A
Total Activin A (follistatin bound and unbound) was measured
using a two-site ELISA as previously described [13]. Affinity-
purified human activin A was used as the assay standard. The
detection limit of the assay for purified human activin A was
50 ng/ml. Intra- and inter assay coefficients of variation were 9%
and 10%, respectively.
Measurement of Inhibin A
Dimeric inhibin A was measured using a two-site ELISA
described previously [13]. The sensitivity of the assay was 2 pg/ml
and the intra- and inter assay variations were 5.2% and 6.5%,
respectively.
sEndoglin and sFlt-1 ELISA
Commercial assays from R&D systems (Abingdon, Oxford, UK)
were used to measure sFlt-1 (kits) and soluble Endoglin (Duo sets).
All samples were assayed in duplicate. The minimum detection
limit of the sFlt-1 ELISA was 31.3 ng/ml and sEng was 62.5 ng/
ml. Inter and intra assay variations for both assays were ,12%.
Statistical analysis
Non parametric tests were carried out as data were not normally
distributed. To analyse the effect of labour and placental
separation at Caesarean section on the release of activin A,
Inhibin A, sFlt-1-1 and sEng, the Mann-Whitney U test was used
for analysis to compare the unpaired data and Wilcoxon test for
the paired data. Data expressed as median (ranges). Significance
set at P,0.05. Statistical analyses were carried out using
GraphPad Prism version 4.0 (GraphPad Inc., San Diego, CA).
Results
The clinical characteristics of each group are presented in
Table 1. There were no significant differences between the two
groups in terms of age or parity, but there was a significant
difference in the gestation at delivery as patients with pre-
eclampsia delivered early compared to normal pregnant women.
All maternal notes were reviewed to check for smoking status and
none of the women were known smokers. Maximum blood
pressure and maximum proteinuria were significantly increased in
the pre-eclampsia group compared to the normal pregnant group.
The median duration of the first stage of labours (ie onset of labour
until full dilatation) varied between 340 min (130–900 range) for
the normal pregnant group and 188 min (90–645) for the pre-
eclampsia group. However this was not statistically significant.
Maternal serum activin A
In the labouring group, the pre-labour values were significantly
higher in pre-eclampsia (19.8(8.3–79)) women compared to the
controls (8.8(4.6–28)), (Fig 1A & 1B). In normal pregnancy, during
labour there was no significant increase compared to pre-labour
levels of activin A at full dilatation; however the levels declined
rapidly within 24 hours of delivery (2.5(1.06–4.8)). In pre-
eclampsia, there was a significant increase with full dilatation
compared to pre-labour (265%, P,0.05) and with placental
delivery the levels rapidly declined to 3.2(0.9–68.5)after 24 hr of
delivery (full dilatation vs 24 hr p,0.001).
The plasma levels of activin A in the Caesarean section group
are shown in Fig 1C and D. The levels of activin A in pre-
eclamptic women were significantly higher in pre-delivery samples
compared to normal pregnant (25(7.3–29.2) ng/ml vs 8.3 (4.2–
23.4); p,0.01 respectively). With placental separation, the levels of
circulating activin A declined rapidly and dropped significantly
after 24 hours in normal pregnancy to 1.8(0.9–19) ng/ml (,80%,
p,0.01) and in pre-eclampsia declining to 2.4(1.2–11.9)ng/
ml(88%, p,0.01), suggesting the placenta is the major source of
increased levels of activin A in pre eclamptic women.
Maternal serum inhibin A
In the labouring group, the pre-labour values of inhibin A in
pre-eclampsia were (944.7 (272–5274) pg/ml) women compared
to normal pregnancy (697.5 (78–1305) pg/ml) (figure 2A & B).
During labour, there was no increase in plasma levels in normal
pregnant women but in pre-eclampsia women, inhibin A levels at
Table 2. Elective Caesarean Section study.
Patient characteristics Normal pregnant Pre-eclamptic women P value
N=10 N=10 Mann Whitney U test
Maternal age (years) 33 (5.7) 34 (5.3) Ns
Nulliparity (%) 10 80 -
Gestation at sampling/delivery (weeks) ** 39 (0.5) 35 (4.3) ,0.01
BMI 25.2(0.7) 26.6(1.9) ns
Smoking none none -
Diastolic BP at sampling (mmHg) 63(9.4) 96 (10.13) ,0.01
Systolic BP at sampling (mmHg) 118(13.6) 153(21.3) ,0.001
Maximum diastolic BP (mmHg) 80 (7.7) 117 (10.13) ,0.001
Maximum systolic BP (mmHg) 133 (7.6) 179(17.9) ,0.001
Maximum 24 hr proteinuria (gms) Not available 3541(739–18293) -
Birth weight (g) 3624 (445.5) 2024 (831) ,0.01
Placental weight(g) 714 (164) 468(182.5) ,0.05
SGA (Birth weight ,10
th centile for gestation) none 60% -
doi:10.1371/journal.pone.0004453.t002
TGF Beta Proteins in Labour
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pre-delivery values (944.7 (272–5274) pg/ml), although this
increase did not reach statistical significance. Following placental
delivery, the levels rapidly declined after 24 hr in normal
pregnancy (p,0.01) and pre-eclamptic women (p,0.01). Inhibin
A measured pre-delivery in the Caesarean section sub group of
study was twofold higher (p,0.05) in pre-eclamptic women (2372
(244–10574) pg/ml) compared to normal pregnant (821(452–
3523) pg/ml). The levels declined with placental delivery and after
24 hours declined further to 62.5(39–3191) (,95%, p,0.01) in
normal pregnancy and) in pre-eclamptic women to 39(39–63) pg/
ml (98%, p,0.01 (Fig 2C & D).
Maternal serum soluble Flt-1
The level of sFlt-1in the pre-labour samples of pre-eclamptic
women (10.1 (0.6–45) ng/ml) in the labour group was nearly two-
fold higher (p,0.05) than in normal pregnancy (4.9 (1.6–16.2) ng/
ml). In normal pregnancy, during labour, (Fig 3A) there was no
significant change in sFlt-1 levels at full dilatation, although an
increasing trend was noted it probably did not achieve statistical
significance due to small sample size SFlt-1 levels significantly
decreased after 24 hours (82% p,0.007) of delivery. However, in
pre-eclamptic women, the levels of plasma sFlt-1 increased during
labour (,180%, p,0.05) and significantly (80%, p,0.05) declined
after 24 hr (Fig 3B).
The levels of plasma sFlt-1 were 3 times higher in the pre-
delivery samples of pre-eclamptic women(24.3 (7.6–77) ng/ml) in
the Caesarean section group compared to normal pregnancy pre-
delivery values of 7.9 (2.1–16.8) ng/ml (p,0.001). Furthermore,
the pre-delivery levels in women with pre-eclampsia in the
Caesarean section group at 34 weeks were 24.3 (7.6–77) ng/ml
compared to the levels of 10.1 (0.6–45) ng/ml in the pre-eclamptic
Figure 1. Activin A levels (median (ranges) ng/ml) in maternal plasma during labour (A,B) and Caesarean section (C,D) in normal
pregnancy (n=10) and women with pre-eclampsia (n=10). In normal pregnancy labour (A) there was a significant decline in activin A levels
by 24 hr (a**p,0.01, pre-labour vs 24 hr, b ***p,0.001-full dilatation vs 24 hr, and c***p,0.001-placental delivery vs 24 hr. In pre-eclampsia labour
(B) there was a significant increase in levels of activin A, (a*p,0.05 pre-labour vs full dilatation) and a significant decline postpartum (a*p,0.05 pre-
labour vs 24 hr, b***p,0.001-full dilatation vs 24 hr, and c**p,0.01-placental delivery vs 24 hr). At Caesarean section a significant decline in levels of
activin A by 24 hr was noted with placental delivery in normal pregnancy and pre-eclampsia (C,D). (NP a*p,0.05 and PE, a ***p,0.001 placental
delivery vs 24 hr).
doi:10.1371/journal.pone.0004453.g001
TGF Beta Proteins in Labour
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(p=0.004). In this cohort of the study in both normal and pre-
eclamptic women the levels declined rapidly (NP 80%, P,0.05,
PE ,90%,p,0.001) following delivery and a further decline in
levels was observed 24 hrs post delivery (Fig 3C & D).
Maternal serum sEndoglin
The pre-labour values of sEndoglin levels in the labour group
were three fold higher in pre-eclamptic women (188 (131–359)ng/
ml) compared to normal pregnancy (52.2 (43–92) ng/ml) prior to
start of labour (P,0.0001, figure 4A & B). During labour, there
was no increase in plasma levels in normal pregnant women or in
the pre-eclamptic women. Following placental delivery, the levels
rapidly declined after 24 hrs to 22.2 (17.5–30) ng/ml normal
pregnancy (p,0.01) and to 123 (57–219) ng/ml in pre-eclamptic
women (p,0.01).
sEndoglin measured pre-delivery in the Caesarean section sub
group of study was three fold higher in pre-eclamptic (288(106–
499)) compared to 96.4 (58–161) ng/ml in normal pregnant
women (p,0.001). The levels declined with placental delivery and
by 24 hours declined by ,65% to 27 (22–110)ng/ml, (p,0.01) in
normal pregnancy, and by ,55% to 120(52–259)ng/ml, (p,0.01)
in pre-eclamptic women suggesting extra placental source(s) for the
increased levels of sEng in pre-eclampsia (Fig 4C and D).
Discussion
This study confirms that maternal circulating levels of activin A,
inhibin A, sFlt-1 and sEng are significantly higher in pre-eclampsia
Figure 2. Inhibin A levels (n=10) in maternal plasma during labour and Caesarean section. Median and ranges for inhibin A levels pg/ml
in labour (A, B). In normal pregnancy labour (A) there was a significant decline in inhibin A levels by 24 h (a**p,0.01-prelabour vs 24 hr, full dilatation
vs 24 hr, and b* p,0.05-placental delivery vs 24 hr. A similar decline was present in PE labour (B) (a*p,0.05, a-pre-labour vs 24 hr, b **p,0.01-
placental delivery vs 24 hr), but the increase noted between pre-labour and full dilatation in pre-eclamptic women was not significant. At Caesarean
section (C,D) a significant decline in levels of inhibin A by 24 hr was noted with placental delivery. (NP and PE a**p,0.01 placental delivery vs 24 hr).
doi:10.1371/journal.pone.0004453.g002
TGF Beta Proteins in Labour
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with other reports [12,14,28–29,16,19]. This is the first study to
report the changes in these TGF beta proteins at parturition in
pre-eclamptic patients to study if the process of labour affects these
proteins in maternal circulation. Interestingly, in labour at full
dilatation pre-eclamptic patients had significantly higher levels of
activin A and sFlt-1 compared to pre-labour levels, suggesting the
process of labour and/or induction of labour may increase
maternal circulating levels of these proteins in pre-eclampsia.
Activin A levels were higher in labour compared to Caesarean
section in normal pregnancy consistent with a previous study [27].
However, sFlt-1 levels were not altered in the normal pregnant
women in labour indicating that these changes are specific to
patients with pre-eclampsia. Inhibin A and sEng levels were not
significantly altered in both groups in labour.
The levels of activin A and inhibin A were higher in the plasma
of pre-eclamptic women who had a Caesarean section around 34
weeks, compared to the pre-delivery levels in the pre-elamptic
women in whom labour was induced. This finding is consistent
with our previous observation that patients with early onset pre-
eclampsia have higher levels of inhibin A and activin A [14]. In the
Caesarean section subgroup of the study, levels of activin A and
inhibin A declined rapidly post delivery in normal pregnancy
(,80%) and preeclampsia (88%). Previous studies have shown that
the major source of maternal circulating levels of activin A and
inhibin A is the placenta [12]. The rapid decline of the plasma
levels of these proteins seen here following placental delivery in
both groups confirms the placenta as the main source of these
proteins in maternal circulation. Schneider-Kolsky et al [32]
performed a longitudinal study of nine normal pregnant women
Figure 3. Median and ranges (n=10) for sFlt-1 levels (ng/ml) in maternal plasma during labour (A,B) and Caesarean section (C,D) in
normal pregnancy and women with pre-eclampsia. In normal pregnancy labour (A) the levels showed a significant decline by 24 hr
(a**p,0.01-full dilatation vs 24 hr, and b***p,0.001-placental delivery vs 24 hr). In pre-eclampsia labour (B) a significant increase in sFlt-1 levels was
noted (a*p,0.05, -pre-labour vs full dilatation) and the levels declined post-delivery (b*p,0.05-full dilatation vs 24 hr). At Caesarean section (C,D) a
significant decline in levels of sFlt-1 by 24 hr was noted compared to those at placental delivery (NP a*p,0.05 and PE b***p,0.001, placental delivery
vs 24 hr).
doi:10.1371/journal.pone.0004453.g003
TGF Beta Proteins in Labour
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Activin A levels in labour in a normal pregnancy compared to pre-
delivery values. Although the findings were similar in normal
labour, in women with pre-eclampsia there was a significant
increase in the levels of activin A during labour (pre labour vs full
dilatation) and a rapid decline after placental delivery (declined by
90% in 24 hr).
Several studies have reported high levels of circulating sFlt-1 in
maternal serum in pre-eclampsia [15,33–35], and it has been
speculated to be causal to the maternal endothelial cell damage
[17]. In this study, we report for the first time that levels of sFlt-1
increased at full dilatation compared to pre-labour in pre
eclampsia. However, in our study, the rate of decline after
placental delivery by 24 hr was not different between normal
pregnancy and pre eclampsia in Caesarean section (NP 80%, PE
90%) and labour groups (NP 82%, PE 80%) as reported previously
– [36]. In the previous study, plasma sFlt-1 levels were measured
at some time in the 48 hours post delivery as the percent change of
the serum sFlt1 concentration between delivery and postpartum.
The values were then adjusted for the hours between the sample
collections. The inherent weakness in this study was the
assumption that the actual decline post delivery is linear. In our
study we show a trend in post delivery decline as samples from all
patients were taken at specified time points and more frequently.
Consistent with previous reports, in this study we report
elevated levels of sEndoglin in pre-eclampsia [37]. In addition,
for the first time we report a rapid decline of this factor after
placental delivery. The percentage of decline in sEng in normal
pregnancy was ,65% after 24 hr delivery compared to .55% in
pre-eclamptic patients. However, the process of labour does not
significantly affect the levels of sEng in pre-eclampsia or normal
pregnancy.
We acknowledge that one of the limitations of this study is the
inability to match the cases and controls for gestation. This is an
intrinsic problem faced by researchers in this field as pre eclamptic
women, by the nature of the pathology, are usually delivered
before term. However, as the primary aim of this study was to
observe the trend of levels of these factors within a cohort, it is less
likely that this could bias the results.
We hypothesize that labour as a possible model for a hypoxia
reperfusion insult and this is suggested by several indirect
evidences. Doppler studies have shown a correlation between
uterine artery resistance and the strength of the contractions
during labour [39–40]. The contractions of labour are known to
Figure 4. sEndoglin levels in maternal plasma during labour (A, B) and Caesarean section (C,D). Median and ranges for sEndoglin ng/ml.
In normal pregnancy labour (A) the levels declined by 24 hr (a***p,0.001, pre-labour vs 24 hr, b**p,0.01-full dilatation vs 24 hr, and placental
delivery vs 24 hr). In pre-eclampsia labour (B) a similar decline by 24 h was noted (a*p,0.05, pre-labour vs 24 hr, full dilatation vs 24 hr, and placental
delivery vs 24 hr). At Caesarean section (C,D) a significant decline in levels of sEndoglin by 24 hr was noted with placental delivery in both normal
pregnancy and pre-eclampsia (a**p,0.01).
doi:10.1371/journal.pone.0004453.g004
TGF Beta Proteins in Labour
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severe enough to influence the feto-placental circulation [41]. The
intermittent periods of hypoxia due to contraction are followed by
reperfusion of the tissues, which leads to increased oxygen tension
and the generation of reactive oxygen species in the placenta [42].
In addition, evidence of increased oxidative stress markers has
been found in laboured placentas, the expression of these markers
being related to the duration of labour [43–44].
From our study it can be postulated that the levels of hypoxia
ischaemia induced by labour are not severe enough to stimulate
materno-placental release of activin A and inhibin A release in
normal pregnancy. In contrast, in pre-eclamptic women, a
condition characterised by chronic placental hypoxia, the contrac-
tions of labour could exacerbate the effect of hypoxia leading to an
increased release of activin A. However there could be additional
pathways which contribute to the plasma levels. Exposure to pro-
inflammatory cytokines could be a possible mechanism for the rise
in serum activin A in pre-eclampsia [45]. In contrast, inhibin A was
stimulated modestly by IL-1b and not by other cytokines, indicating
that the mechanisms involved in the rise of activin A and inhibin A
in pre-eclampsia are controlled differentially. The contractions of
labour in a compromised placenta due to pre-eclampsia could add
to the burden of pro-inflammatory cytokines, this could explain the
significant rise of activin A compared to inhibin A in pre-eclamptic
labour. In addition the increased circulating activin A levels
observed in PE may result from both placental and systemic
sources, including inflammatory leukocytes and activated endothe-
lium [13]. In vitro studies have shown that oxidative stress, induced
by xanthine/xanthine oxidase, stimulates activin A production and
secretion from placental explants and endothelial cells [26], and
Many et al [44], have shown that Xanthine oxidase is elevated in
labour. It is possible that the increased oxidative stress in labour
could be one of the mechanisms which contribute to the increased
levels in pre-eclampsia.
The mechanism of increased sFlt-1 in pre eclampsia is still not
known. Although the placenta appears to be the major source of
circulating sFlt-1 [46] other sources, such as activated mononuclear
cells, may also contribute to the rise in circulating levels [47]. We
have some understanding as to how these anti angiogenic proteins
(sFlt-1 and sEndoglin) influence the maternal syndrome, but very
little information on its effects in the placenta. In vitro, cytotropho-
blast is known to produce sFlt-1 under reduced oxygen tension [48]
and sFlt-1 inhibits trophoblast migration and differentiation [49].
Makris et al [25] show that decrease in blood flow to the utero
placental compartment in primates leads to development of
hypertension and proteinuria and a renal lesion resembling the
endotheliosis of pre-eclampsia in the human. These changes were
associated with a tenfold increased circulating concentrations of
sFlt-1. In our study, the contractions of labour seem to contribute to
a threefold increaseinsFlt-1 atfulldilation compared topre-labour.
The differencein levels noted compared to primates could be dueto
a possible difference in the mechanisms involved in production and
clearance of these proteins.
Pre-eclampsia is also characterized by high circulating concen-
trations of soluble endoglin, a novel anti angiogenic substance that
has been recently shown to synergize with sFlt-1 in the
pathogenesis of pre-eclampsia. Excess levels of the two endogenous
circulating anti-angiogenic proteins have been postulated to inhibit
VEGF and TGF-b1 signalling respectively, contributing to
endothelial dysfunction in the vasculature. Although our study
did show that the levels of soluble endoglin increased in pre-
eclampsia but labour did not lead to enhanced levels. Serum levels
of these proteins are a reflection of the production and clearance
from different sources. Very little information is available on how
sFlt-1 and sEndoglin are cleared from the circulation, although
there is some evidence of increased urinary levels possibly due to
glomerular leakage which has been noted to be increased in severe
compared to mild pre-eclampsia [51].
Cindrova-davies et al [52] found increased evidence of oxidative
stress, inflammatory cytokines, angiogenic regulators and apopto-
sis in laboured placentas. They found that this effect was more
pronounced in long labours. The increased levels of Activin A and
sFlt-1 in labouring women with preeclampsia could contribute to
the inflammatory response and endothelial dysfunction. We can
speculate that the increased plasma levels of the TGF proteins
which are a result of production and clearance, compounded by
the oxidative stress noted in labour could sustain the inflammatory
response postpartum [53–54]. We have previously shown that the
contractions in labour leads to increased shedding of placental
debris (syncytiotrophoblast microparticles-STBM) [55], possibly
due to the hypoxia reperfusion insult of the placenta. The increase
of sFlt-1 noted in labour in women with pre-eclampsia was found
to positively correlate with the levels of STBM (unpublished
observations), suggesting that the shedding mechanisms are related
or sFlt-1 is expressed on the STBM. Indeed Sela et al [56] have
recently described increased expression of placental sFlt1-14
(variant of sFlt-1), in the syncytial knots in women with pre-
eclampsia. Further research to explore these possibilities is
currently under investigation in our laboratory.
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